[1] 王宇明. 慢性乙型肝炎抗病毒治疗的停药问题.中华临床感染病杂志,2010,3(1):68-72. [2] 中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南(2010年版). 实用肝脏病杂志,2011,14(2):81-89. [3] Reijnders JG,Perquin MJ,Zhang N,et al. Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B.Gastroenterology,2010,139:491-498. [4] Liaw YF,Kao JH,Piratvisuth T,et al. Asian-pacific consensus statement on the management of chronic hepatitis B:a 2012 update. Hepatol Int,2012,6(3):531-561. [5] 庄辉. 2012年版欧洲肝病学会慢性乙型肝炎病毒感染管理临床应用指南更新要点. 中华肝脏病杂志,2012,20(6):427-429. [6] Monto A,Schooley RT,Lai JC,et al. Lessons from HIV therapy applied to viral hepatitis therapy:summary of a workshop. Am J Gastroenterol,2010,105(5):989-1004. [7] Chen XF,Chen XP,Ma XJ,et al. Optimized strategy:sequential peginterferon alfa-2a therapy in entecavir-treated patients CHB without satisfactory end-point led to HBeAg seroconversion. J Hepatol,2013,581:s300-s301. [8] Li Q,Dong G,Yu J,et al. Adding peginterferon alfa-2a on nucleos(t)ide analogues therapy improves HBeAg seroconversion and HBsAg decline in HBeAg-positive chronic hepatitis B patients who have achieved virological responses. J Hepatol,2013,581:s307-s308. |